EMBLA.CO Stock — Price, Charts & Analysis

Embla Medical hf (EMBLA.CO) has a trailing P/E of 20.95x and a forward P/E of 16.84x. This places EMBLA.CO in a moderate earnings multiple territory based on the valuation data currently available on Worldtickers.

EMBLA.CO trades with 20.95x earnings on Worldtickers. Use valuation together with growth, balance sheet strength, and risk before deciding whether EMBLA.CO looks overvalued or undervalued.

EMBLA.CO's P/E of 20.95x should be judged against Healthcare peers, growth rate, margins, and balance sheet quality. A lower P/E may indicate value, while a higher P/E often means investors expect stronger future growth.

EMBLA.CO's trailing EPS is DKK 1.42 and forward EPS is DKK 1.77. Reported earnings growth is 36.00%, which helps show current profit momentum.

EPS, or earnings per share, shows how much profit Embla Medical hf generated for each share. EMBLA.CO's trailing EPS is DKK 1.42, and investors usually prefer EPS that is positive and growing over time.

Embla Medical hf has a market cap of DKK 12.66B, making EMBLA.CO a large-cap stock based on the current market value shown on Worldtickers.

EMBLA.CO's latest stock price on Worldtickers is DKK 29.75. The latest move is DKK 0.00 or 0.00%. Use the live quote, chart, volume, and 52-week range to judge the current trading context.

EMBLA.CO's quote includes a latest price of DKK 29.75. The market open is DKK 29.65. Previous close is DKK 29.75. The intraday range is DKK 29.55 to DKK 29.80.

EMBLA.CO is up in the latest quote, with a move of DKK 0.00 or 0.00%. To understand the reason, compare this move with news, earnings updates, analyst changes, sector performance, and market-wide direction.

EMBLA.CO generated DKK 984.45M in trailing revenue. Revenue growth is 11.30%, which helps show whether demand is expanding or slowing.

EMBLA.CO's revenue growth is 11.30%, which is a strong demand signal in the latest available data. Investors usually compare revenue growth with margin trends and valuation to judge whether growth is profitable.

Yes, EMBLA.CO shows positive profitability metrics in the latest data available on Worldtickers. Net income to common shareholders is DKK 93.95M.

Gross margin is 62.31%. Margins show how efficiently Embla Medical hf turns revenue into profit.

Embla Medical hf carries DKK 533.97M and holds DKK 98.78M in cash.

EMBLA.CO holds DKK 98.78M on its balance sheet.

EMBLA.CO's book value per share is DKK 14.00.

EMBLA.CO's five-year average dividend yield is 39.00%. Use this alongside current yield, payout ratio, and cash flow to understand whether today's dividend looks high or low versus recent history.

Institutions hold 79.05% of EMBLA.CO shares. Insiders hold 11.69% of shares. Ownership mix helps investors understand how much of Embla Medical hf is held by professional investors and company insiders.

EMBLA.CO has 425.64M shares outstanding. Float shares are 156.55M. Share count affects market cap, EPS, ownership percentages, and the impact of buybacks or dilution.

Insider activity can be useful context for EMBLA.CO, especially when multiple executives buy shares with their own money. Insider selling is harder to interpret because executives may sell for taxes, diversification, or planned compensation reasons.

Forward EPS for EMBLA.CO is DKK 1.77. Earnings growth is 36.00%. Revenue growth is 11.30%. For earnings, investors usually watch EPS, revenue, margins, guidance, and management commentary.

EMBLA.CO's trailing EPS is DKK 1.42. Forward EPS is DKK 1.77. Use the earnings section on the page to compare reported results, estimates, and trend changes when those datasets are available.

EMBLA.CO is in the Healthcare sector. Its earnings multiple is 20.95x. Its latest displayed growth metric is 11.30%. Compare these figures with sector peers before deciding whether Embla Medical hf is stronger or weaker than average.

EMBLA.CO trades at DKK 29.75. The stock trades at 20.95x earnings. Whether to invest depends on your risk tolerance, time horizon, diversification, and view of Embla Medical hf's fundamentals.

EMBLA.CO risks include company execution, valuation, competition in Healthcare, interest rates, and broad market volatility. Beta is 0.46, which helps estimate market sensitivity. No single stock should be evaluated without portfolio context.

EMBLA.CO should be compared with companies in Medical Devices. Its earnings multiple is 20.95x. Useful comparison points include revenue growth, margins, debt, cash flow, valuation, analyst targets, and price momentum.

Embla Medical hf (EMBLA.CO) operates in Healthcare, specifically Medical Devices. Embla Medical hf., together with its subsidiaries, provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It operates through three segments: Prosthetics and Neuro Orthotics, Bracing and Supports, and Patient Care. The Prosthetics and Neuro Orthotics segment offers mechanical products, such as lower and upper limb loss or difference; and bionic products, such as microprocessor-controlled feet, knees, hands, fingers, and neuro orthotic joints. The Bracing an

EMBLA.CO trades on Copenhagen. Exchange context matters because trading hours, liquidity, currency, and settlement rules can differ across markets.

EMBLA.CO stock is priced in DKK on Worldtickers. Currency matters for international investors because exchange-rate moves can affect local-currency returns.

Embla Medical hf's official website listed on Worldtickers is www.emblamedical.com. Investor relations pages are useful for earnings releases, annual reports, filings, and shareholder presentations.

Embla Medical hf employs about 4.5K people based on the latest company profile data available on Worldtickers. Workforce size helps investors understand company scale and operating complexity.

Embla Medical hf is headquartered in Reykjavik, Iceland. Headquarters location can matter for currency, regulation, tax, labor market, and regional economic exposure.

EMBLA.CO is in the Healthcare sector and the Medical Devices industry. Sector context helps investors compare valuation, growth, margins, and risk against similar companies.

EMBLA.CO has traded between DKK 25.00 and DKK 37.90 over the past 52 weeks. At DKK 29.75, it is 21.50% below the high and 19.00% above the low. The 52-week range helps gauge long-term price momentum.

EMBLA.CO is between its 50-day and 200-day moving averages, which suggests a mixed trend setup. Its 50-day moving average is DKK 27.53 and its 200-day moving average is DKK 29.82.

EMBLA.CO's RSI is 66.47. Readings below 30 are commonly viewed as oversold, above 70 as overbought, and the current reading suggests a neutral momentum setup.

EMBLA.CO's latest RSI reading is 66.47, which points to neutral momentum today. Traders usually confirm RSI with volume, trend, and nearby support or resistance.

Key support for EMBLA.CO is near DKK 26.65. Key resistance is near DKK 30.15. Breaks above resistance or below support can change the short-term technical setup.

EMBLA.CO's nearest reported support level is DKK 26.65. A clean break below support can weaken the short-term setup, while repeated bounces can show demand.

EMBLA.CO's nearest reported resistance level is DKK 30.15. A breakout above resistance can improve momentum, especially when volume confirms the move.

EMBLA.CO trades about 101.2K shares daily on average. The latest displayed volume is 26.87K shares. Volume helps show liquidity and whether trading interest is unusually high or low.

EMBLA.CO's MACD is 0.01, which is a positive momentum reading. MACD should be reviewed with price trend, moving averages, RSI, volume, and support or resistance levels.

EMBLA.CO is between its 50-day and 200-day moving averages, which suggests a mixed trend setup. RSI is 66.47 (neutral). MACD is bullish. Nearest support is around DKK 26.65. Resistance is around DKK 30.15. A buy decision should also consider valuation, earnings quality, risk tolerance, and position sizing.

MA20 is DKK 28.92 (2.87% from price). MA50 is DKK 27.53 (8.08% from price). MA200 is DKK 29.82 (-0.24% from price). The moving-average stack helps separate short-term momentum from long-term trend risk.

The server report currently confirms daily moving-average levels rather than a separate EMA-only value. EMBLA.CO's MA20 is DKK 28.92. MA50 is DKK 27.53. For EMA-specific overlays, use the live chart indicators and compare EMA direction with RSI, MACD, volume, support, and resistance.

EMBLA.CO's pivot is near DKK 29.58. Support is near DKK 26.65. Resistance is near DKK 30.15. Price holding above pivot can support a constructive setup, while rejection near resistance can cap momentum.

The next lower support zone for EMBLA.CO is near DKK 29.17. The next upper resistance zone is near DKK 30.40. These levels help define risk and possible follow-through zones after a breakout or breakdown.

EMBLA.CO's Bollinger range is roughly DKK 27.28 to DKK 30.56. Band width is near 11.37%. Price near the upper band can show stretched upside momentum, while price near the lower band can show downside pressure or a possible mean-reversion zone.

EMBLA.CO's ATR-based typical daily range is about 2.00%. ATR helps size risk because wider ranges usually require wider stops or smaller position sizes.

Latest volume is 26.87K shares. Average volume is about 101.2K shares. Breakouts with rising relative volume are usually more reliable than moves on light participation.

EMBLA.CO's all-time high shown on Worldtickers is DKK 57.80. Its all-time low is DKK 7.15. All-time levels provide long-range context, but recent fundamentals and market conditions matter more for current decisions.

EMBLA.CO has a beta of 0.46, meaning it has historically been less volatile than the broad market. Beta is useful for judging how much a stock may move during broad market swings.